Sugi Predict

Sugi Predict / Compounds / SCHEMBL3529537

SCHEMBL3529537

SCHEMBL3529537

O=C(O)CNC(=O)c1c(O)c(-c2c[nH]c3ccccc23)cc2nccnc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGLN3 Q9H6Z9 4/20 0.61
▸ PDE10A Q9Y233 1/20 0.45
▸ EGLN1 Q9GZT9 4/20 0.39
▸ GSK3B P49841 3/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ FTO Q9C0B1 2/20 0.38
▸ BBOX1 O75936 1/20 0.38
▸ KDM5B Q9UGL1 1/20 0.38
▸ KDM2A Q9Y2K7 1/20 0.38
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ BRD4 O60885 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ HDAC3 O15379 1/20 0.37
▸ HDAC4 P56524 1/20 0.37
▸ HDAC1 Q13547 1/20 0.37
▸ HDAC7 Q8WUI4 1/20 0.37
▸ HDAC2 Q92769 1/20 0.37
▸ HDAC10 Q969S8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3522213 0.82 EGLN3 (0.83) EGLN3EGLN1FTOKDM5BKDM2A
SCHEMBL3522039 0.80 EGLN3 (0.67) EGLN3EGLN1FTOBBOX1KDM5B
SCHEMBL3532916 0.80 EGLN3 (0.61) EGLN3EGLN1FTOBBOX1KDM5B
SCHEMBL3522233 0.80 EGLN3 (0.61) EGLN3EGLN1FTOBBOX1KDM5B
SCHEMBL3766921 0.80 EGLN3 (0.69) EGLN3EGLN1FTOBBOX1KDM5B
SCHEMBL3763287 0.78 EGLN3 (0.70) EGLN3EGLN1FTOBBOX1KDM5B
SCHEMBL3533480 0.77 EGLN3 (0.69) EGLN3EGLN1FTOKDM5BKDM2A
SCHEMBL3757210 0.76 EGLN3 (0.78) EGLN3EGLN1FTOKDM5BKDM2A
SCHEMBL3517885 0.76 EGLN3 (0.67) EGLN3EGLN1GSK3BKDM4EMAPT
SCHEMBL3522129 0.76 EGLN3 (0.67) EGLN3EGLN1GSK3BKDM4EFTO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 — — US claimed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 — — EP claimed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 — — WO claimed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 — — US disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 — — US disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 — — US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 — — EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 — — WO disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 EGLN3 2/4885PDE10A 2604/4885EGLN1 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.